1 261

Cited 3 times in

A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer

Authors
 Hee Man Kim  ;  Kyong Joo Lee  ;  Jihye Cha  ;  Moon Jae Chung  ;  Seungmin Bang  ;  Jinsil Seong  ;  Si Young Song  ;  Seung Woo Park 
Citation
 CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.74(4) : 861-865, 2014 
Journal Title
 CANCER CHEMOTHERAPY AND PHARMACOLOGY 
ISSN
 0344-5704 
Issue Date
2014
MeSH
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Biliary Tract Neoplasms/drug therapy* ; Biliary Tract Neoplasms/pathology ; Chemoradiotherapy/methods* ; Disease-Free Survival ; Drug Combinations ; Drug Screening Assays, Antitumor ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Oxonic Acid*/administration & dosage ; Oxonic Acid*/adverse effects ; Pilot Projects ; Tegafur*/administration & dosage ; Tegafur*/adverse effects ; Treatment Outcome
Keywords
S-1 ; Biliary tract cancer ; Concurrent chemoradiotherapy ; Pilot
Abstract
PURPOSE: S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer. METHODS: Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m(2), twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180-200 cGy per fraction was delivered in 25-28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required. RESULTS: Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45-77 years). The median follow-up time was 11.6 months (range 1.9-49.1 months). Fifteen patients (75%) had extrahepatic cholangiocarcinoma, two patients (10%) had intrahepatic cholangiocarcinoma, and three patients (15%) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15%), and stable disease was achieved in 14 patients (70%). The overall response rate was 15%, and the disease stabilization rate was 85%. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15%), neutropenia (10%), and nausea (10%). The median progression-free survival and median overall survival were 5.9 months (range 2.2-9.5 months) and 10.8 months (range 1.1-20.4 months), respectively. CONCLUSIONS: This study shows that S-1-based concurrent chemoradiotherapy is feasible and tolerable in patients with advanced biliary tract cancer. It will be further confirmed in a following large-scale phase II study.
Full Text
http://link.springer.com/article/10.1007%2Fs00280-014-2565-y
DOI
10.1007/s00280-014-2565-y
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Chung, Moon Jae(정문재) ORCID logo https://orcid.org/0000-0002-5920-8549
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/99781
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse